Literature DB >> 19844890

Health-related quality of life in dialysis patients with HCV infection.

Fabrizio Fabrizi1, Piergiorgio Messa, Paul Martin.   

Abstract

Measuring the impact of chronic kidney disease (CKD) treatment on patient quality of life has become increasingly recognized as an important outcome measure. Despite improvements in the treatment of chronic kidney disease, health-related quality of life (HRQOL) is lower than in the general population. HRQOL measures, particularly the Physical Component Summary (PCS), have predictive validity for risk of both mortality and hospitalization in dialysis populations. For every 10-point lower PCS score, the relative risk (RR) of death increases by 29% (RR = 1.29; 95% CI = 1.23 to 1.35; p < 0.001) and the risk of hospitalization increases by 15% (RR = 1.15; 95% CI = 1.11 to 1.19, p < 0.001), according to the Dialysis Outcomes and Practice Patterns Study (DOPPS). Hepatitis C virus (HCV) infection remains prevalent among dialysis patients with a recent meta-analysis showing that anti-HCV seropositive status was an independent and significant risk factor for death in patients on maintenance dialysis. Seven studies with 11,589 unique patients on maintenance dialysis were identified; the summary estimate for adjusted relative risk (aRR) (all-cause mortality) was 1.34 with a 95% confidence interval (CI) of 1.13-1.59. In non-uremic populations HCV diminishes HRQOL, and individuals with HCV scored lower than controls across all scales of the short form 36 (SF-36). Patients achieving sustained virological responses (SVR) scored higher across all scales versus patients without SVR, especially in the physical health domains. Whether the adverse influence of HCV on survival in dialysis population is related to the negative impact of HCV on HRQOL requires further research. Information on HRQOL indices in patients with HCV on maintenance dialysis is extremely limited but the available evidence shows that HCV infection impairs HRQOL, especially in mental aspects, among patients on maintenance hemodialysis.

Entities:  

Mesh:

Year:  2009        PMID: 19844890     DOI: 10.1177/039139880903200801

Source DB:  PubMed          Journal:  Int J Artif Organs        ISSN: 0391-3988            Impact factor:   1.595


  8 in total

Review 1.  Management of patients with hepatitis C infection and renal disease.

Authors:  Chalermrat Bunchorntavakul; Monthira Maneerattanaporn; Disaya Chavalitdhamrong
Journal:  World J Hepatol       Date:  2015-02-27

Review 2.  Hepatic disorders in chronic kidney disease.

Authors:  Fabrizio Fabrizi; Piergiorgio Messa; Carlo Basile; Paul Martin
Journal:  Nat Rev Nephrol       Date:  2010-04-13       Impact factor: 28.314

3.  Treatment of HCV in Renal Disease: Subtle Management Considerations in the Era of Direct-acting Antivirals.

Authors:  Yuval A Patel; Andrew J Muir
Journal:  Curr Hepatol Rep       Date:  2016-11-05

Review 4.  Hepatitis C virus infection in kidney transplantation-changing paradigms with novel agents.

Authors:  Yuvaram N V Reddy; David Nunes; Vipul Chitalia; Craig E Gordon; Jean M Francis
Journal:  Hemodial Int       Date:  2018-04       Impact factor: 1.812

5.  QUALITY OF LIFE IN HEMODIALYSIS PATIENTS.

Authors:  Kousoula Gerasimoula; Lagou Lefkothea; Lena Maria; Alikari Victoria; Theofilou Paraskevi; Polikandrioti Maria
Journal:  Mater Sociomed       Date:  2015-10-05

6.  Health related quality of life in Iranian hemodialysis patients with viral hepatitis: changing epidemiology.

Authors:  Zohreh Rostami; Mahboob Lessan Pezeshki; Azam Soleimani Najaf Abadi; Behzad Einollahi
Journal:  Hepat Mon       Date:  2013-05-30       Impact factor: 0.660

7.  A Better Quality of Life in Hemodialysis Patients With Viral Hepatitis: Is it a Reality?

Authors:  Eghlim Nemati; Mohsen Motalebi
Journal:  Hepat Mon       Date:  2013-11-30       Impact factor: 0.660

8.  Interferon-Based Treatment of Hepatitis C Virus Infection Reduces All-Cause Mortality in Patients With End-Stage Renal Disease: An 8-Year Nationwide Cohort Study in Taiwan.

Authors:  Yueh-Han Hsu; Peir-Haur Hung; Chih-Hsin Muo; Wen-Chen Tsai; Chih-Cheng Hsu; Chia-Hung Kao
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.